AZATHIOPRINE TABLET

Land: Kanada

Sprache: Englisch

Quelle: Health Canada

Wirkstoff:

AZATHIOPRINE

Verfügbar ab:

SANIS HEALTH INC

ATC-Code:

L04AX01

INN (Internationale Bezeichnung):

AZATHIOPRINE

Dosierung:

50MG

Darreichungsform:

TABLET

Zusammensetzung:

AZATHIOPRINE 50MG

Verabreichungsweg:

ORAL

Einheiten im Paket:

100

Verschreibungstyp:

Prescription

Therapiebereich:

IMMUNOSUPPRESSIVE AGENTS

Produktbesonderheiten:

Active ingredient group (AIG) number: 0101830001; AHFS:

Berechtigungsstatus:

CANCELLED POST MARKET

Berechtigungsdatum:

2017-07-31

Fachinformation

_____________________________________________________________________________________
_AZATHIOPRINE Product Monograph _
_ _
_Page 1 of 25_
PRODUCT MONOGRAPH
AZATHIOPRINE
AZATHIOPRINE TABLETS USP
50 MG
IMMUNOSUPPRESSIVE AGENT
SANIS HEALTH INC.
333 CHAMPLAIN ST.
DIEPPE, NEW BRUNSWICK
DATE OF PREPARATION:
E1A 1P2
July 7, 2015
CONTROL #: 184965
_____________________________________________________________________________________
_AZATHIOPRINE Product Monograph _
_Page 2 of 25_
TABLE OF CONTENTS
PART I:
HEALTH PROFESSIONAL INFORMATION
..............................................
3
SUMMARY PRODUCT INFORMATION
......................................................
3
INDICATIONS AND CLINICAL USE
............................................................
3
CONTRAINDICATIONS
.................................................................................
3
WARNINGS AND PRECAUTIONS
................................................................
4
ADVERSE REACTIONS
..................................................................................
8
DRUG INTERACTIONS
..................................................................................
10
DOSAGE AND ADMINISTRATION
..............................................................
12
OVERDOSAGE
................................................................................................
12
ACTION AND CLINICAL PHARMACOLOGY
............................................
13
STORAGE AND STABILITY
..........................................................................
15
SPECIAL HANDLING INSTRUCTIONS
.......................................................
15
DOSAGE FORMS, COMPOSITION AND PACKAGING .............................
15
PART II: SCIENTIFIC INFORMATION
........................................................................
16
PHARMACEUTICAL INFORMATION
..........................................................
16
CLINICAL TRIALS
..........................................................................................
16
TOXICOLOGY
.....................